Cancer Drug Shortages This Week: What to Ask

The legal definition is narrower than the word

In everyday use, "shortage" means your pharmacy does not have it. FDA uses the term differently, and the gap between the two causes a lot of confusion.

The Federal Food, Drug, and Cosmetic Act sets the definition. A drug shortage is a period when demand, or expected demand, in the United States is greater than supply. FDA tracks this at the national level. Manufacturers are required to give it the information.

So a drug is "in shortage" only when supply nationwide is not meeting current demand, or is not forecast to meet it. Your local situation does not enter into that judgment.

Why the same kinds of drug keep running out

FDA names manufacturing quality problems as the most common cause. Others are production delays, hold-ups getting raw materials, sudden jumps in demand, and companies simply stopping production.

That last point is worth stating plainly. FDA cannot require a company to keep making a drug it wants to discontinue, and older drugs are sometimes dropped in favor of newer, more profitable ones.

The pattern that follows explains why cancer care is hit so often. Older sterile injectable drugs are made by few firms, on few production lines. Their raw material suppliers are limited too. Making injectables is complex, and lead times are long. When one company has a problem, the others cannot ramp up quickly.

Many core cancer chemotherapy drugs are exactly that: old, generic, sterile injectables with thin margins and few manufacturers.

The openFDA drug shortages database listed 1,179 current records in early August 2026, out of 1,651 in total. Carboplatin is a platinum chemotherapy used across several cancers. It appeared with dozens of current entries, and the reasons attached to them varied: some said the manufacture of that presentation had been discontinued, some cited a rise in demand, some cited good manufacturing practice requirements, and many said only "other". Injectable methotrexate appeared too. Those entries change constantly. That is why the database, rather than any article, is the thing to check.

Local out-of-stock is a different problem

FDA is direct about this. Reports from hospitals, pharmacies and patients about local supply are usually temporary. They are often about distribution. They resolve when the pharmacy can reorder from its distributor.

Its advice in that situation is practical: check other pharmacies, and ask a provider or pharmacist whether there is an alternative.

The distinction matters because the fix is different. A national shortage means the team needs a clinical plan. A local gap often means a different pharmacy has it today.

FDA does add that local supply problems can sometimes be an early signal of a national one, and it takes reports through a public portal for that reason. Our page on navigating cancer drug shortages and access covers the practical side.

What each source can settle

Source	What it can tell you	What it cannot decide for you
FDA Drug Shortage Database	Whether FDA lists a product as current, resolved or discontinued, and the stated reason	Whether your pharmacy can get supply today
FDA drug shortages FAQ	How a shortage is defined, why they happen, and how to report one	Which substitute is safe for one person's cancer and plan
Oncology team or specialty pharmacy	Timing, dose, alternative drug, prior authorization, or a different pharmacy	A national shortage determination
Insurer	Whether an alternative is covered, and what approval it needs	Whether the alternative is clinically equivalent

One more limit worth naming: FDA says pricing is outside its remit entirely. It points people with price concerns to the Federal Trade Commission. It also warns about a side effect of shortages. Pharmacies receive faxed and emailed offers from unknown distributors at inflated prices. FDA says these should be reported to its Office of Criminal Investigations.

Questions worth asking when a dose is delayed

• Is the medicine unavailable, delayed, being substituted, or waiting on insurance approval? These have four different fixes.
• Is this an FDA-listed national shortage or a local supply gap? The database answers the first half.
• If it is not available by the treatment date, what is the plan: a different drug, a different schedule, or a wait?
• Who is coordinating between the prescriber, the infusion center, the specialty pharmacy and the insurer?
• What gets written in the chart about the change in timing?
• Is there a different site or pharmacy within the same health system that has stock?

When to get checked

A delayed drug does not put symptoms on hold. NCI lists changes that warrant a doctor's attention when they last more than a couple of weeks, and they still apply during a supply problem:

• Fever or night sweats with no known cause.
• Severe tiredness that does not lift.
• Bleeding or bruising for no clear reason.
• Pain after eating, trouble swallowing, or belly pain.
• A change in bowel or bladder habits, or blood in stool or urine.
• New lumps or swelling anywhere, including neck, underarm, abdomen or groin.
• Weight loss or weight gain you cannot explain.

NCI also notes cancer often causes no pain early on, so pain is not the trigger for making contact. Anything new during a treatment gap belongs in a phone call to the team, not in a wait for the rescheduled appointment.

What this does not mean

It does not mean every local access problem is an FDA-defined national shortage. Most are not.

It does not mean anyone should switch, skip, split or stretch a medicine outside the plan their oncology team sets.

It does not mean FDA can advise an individual on an alternative. The agency tracks supply; it does not practice medicine.

And it does not mean the database is complete in real time. It reflects what manufacturers have reported. The deadline allows up to five business days after an interruption begins. Six months of notice is expected for planned discontinuations.

Sources

• FDA, Drug Shortages — https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
• FDA, Frequently Asked Questions about Drug Shortages — https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
• openFDA, Drug Shortages API — https://api.fda.gov/drug/shortages.json
• NCI, Symptoms of Cancer — https://www.cancer.gov/about-cancer/diagnosis-staging/symptoms

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.